conservation strategies, including preoperative anaemia treatment, the use of pharmacological agents to promote haemostasis, and alternatives to donor blood. 11 Anaemia management is furthermore part of the Enhanced Recovery Partnership's guidelines for major surgery. 12 These national agencies have, however, not made detailed recommendations, for example, on treatment thresholds or the methods justified for red cell mass optimization. The 2007 NHSBT national comparative audit 3 identified in their report to our NHS Trust that we did not have a mechanism for ensuring that anaemic patients are identified and treated before THR. In view of the above-mentioned national standards and increasing international recognition that blood conservation is an unmet medical need, 7 12 we designed a local blood management algorithm for primary hip and knee replacement and audited its introduction.
The audit was conducted in three stages, with the following aims: † Retrospective baseline data collection:
W To quantify the baseline transfusion rate for primary arthroplasty in our hospital.
W To determine the prevalence of anaemia according to World Health Organization (WHO) criteria, 13 before primary arthroplasty [haemoglobin (Hb),12 g dl 21 for women and ,13 g dl 21 for men].
Our primary process measure was the proportion of patients presenting for elective arthroplasty with anaemia. The proportion of patients exposed to ABT was our primary outcome. Secondary outcomes were LOS, re-admission after discharge, and the net cost of the programme (drug costs minus any blood product savings).
Methods
The UK National Research Ethics Service classified this project as audit. Our Trust's Caldicott Guardian approved our data security process. We followed the Standards for Quality Improvement Reporting Excellence (SQUIRE) guidelines for reporting the project's effects. 14 Patients who had more than one joint replacement in the period concerned were considered more than once, that is, the unit of analysis was the operation rather than the patient. We did not consider revision, resurfacing, or bilateral procedures.
Institutional practice
Airedale General Hospital performs 400 -500 primary lower limb arthroplasties per year with an NJR reporting rate of .95%. 15 Our ABT rate for THR in the NHSBT 2007 audit was 23% and the national average 25%. 16 The local transfusion guidelines state that ABT is likely to be inappropriate if the haemoglobin (Hb) is .8 g dl 21 in the absence of symptoms attributable to tissue oxygen deficit or continuing bleeding. Thromboprophylaxis and discharge criteria are based on local protocols applicable to all inpatients. Tourniquet use for TKR is universal except when specific contraindications exist. The use of wound drains is at the discretion of individual surgeons; re-infusion drains are universal when drains are used. Intraoperative cell salvage is routine for revision joint replacements but rarely used for primary arthroplasties. The above guidelines and practices remained unaltered over the course of the audit cycle. At baseline, there was no written guideline for how anaemia should be managed before operation. Although there was an agreement that patients may be referred to the haematology service for investigation, this was rarely used. There was also no specific guideline on intraoperative blood conservation measures. The programme introduced change in both these areas.
Baseline data collection
We retrospectively searched our theatres database (TheatreMan, Trisoft Limited, Chesterfield, UK) for all THR or TKR coded between January 2008 and December 2009. These were cross-linked with our patient administration, laboratory, and transfusion databases, using a composite of the patient's name, date of birth, and hospital number as a unique identifier. These databases are subject to regular external audit. To ensure specificity, we excluded any episode where the data set contained internal inconsistencies (Fig. 1) . We checked the results against our data submitted to the UK National Joint Registry (NJR) and NHSBT.
We collected patient data (birth date and sex), preoperative data (last preoperative Hb, admission date, and ASA score), and operative data (operation date, admitting consultant, and operating surgeon). The postoperative data were nadir Hb (defined as the lowest Hb between operation and discharge), discharge Hb, discharge date, and any admissions within 90 days from discharge. We established the total number of red cell units transfused for each patient during the primary admission. We calculated the perioperative Hb loss as a surrogate for total blood loss (preoperative Hb minus nadir Hb) and LOS (discharge date minus admission date).
Baseline statistical analysis
We conducted multivariate regression analyses, using linear and logistic regression for continuous and binary data, respectively. The effect of operation site (hip or knee), age, sex, operating surgeon, preoperative Hb, and Hb loss on outcome (ABT, LOS, and re-admission) were explored in the models. We used Stata SE (Version 9.2, StataCorp LP, College Station, TX, USA).
Algorithm design and implementation
We presented the baseline data to our anaesthetic, orthopaedic surgery, and haematology departments. Agreement over treatment thresholds, pathways, and continuing audit was achieved by discussion, using published algorithms, 17 -19 Blood management and arthroplasty outcome BJA iron therapy (and/or investigation of their anaemia per se) if this was indicated. Patients offered parenteral iron or erythropoietin-a (EPO) were referred to one of two anaesthetists (A.K. or L.A.C.). Consent for treatment and any adverse events were documented via usual Trust processes. Drug treatments were within license. In treated patients, Hb was also measured in the final week before surgery.
Clinicians were advised to use intraoperative blood conservation measures if the presenting Hb was ,13 g dl 21 (THR) or ,12 g dl 21 (TKR), and there were no contraindications ( Fig. 4 ), but this was not specifically audited and largely left to the team's discretion.
Before-and-after comparisons
We prospectively collected data for all primary THR and TKR performed from April to December 2010. We then compared these against the retrospective controls on an intention-to-treat basis, using GraphPad Prism Version 5.04 (GraphPad Software, La Jolla, CA, USA). We compared binary outcomes using Fisher's exact test. We tested whether continuous data followed a Gaussian distribution (the Kolmogorov-Smirnov test) and conducted t-tests, or the Mann-Whitney tests as appropriate. Data are presented as median [inter-quartile range (IQR)]; we estimated effect size (ES) and odds ratios (ORs) as appropriate and these are presented as ES or OR [95% confidence interval (CI)]. Statistical significance was assumed at a twotailed P-value of ,0.05.
Results

Baseline data set
Patients and procedures
The coding search identified 761 procedures. Forty-four were excluded, resulting in analysis of 361 THR and 356 TKR ( Fig. 1 ). During the same period, our hospital reported 426 and 381 THR and TKR to the UK NJR. A total of 412 joint replacements were performed on female patients and 305 on males. Transfusion, admission, and discharge data were available for all patients in this study. Preoperative Hb results were successfully linked to operative records for 684 patients. The prevalence of preoperative anaemia was 24.3% (166/684; Tables 1 and 2 Incorporating the individual surgeon in the regression analyses did not produce significantly better model fit (P.0.2 in all cases; r,0.01, where r is the proportion of the total variance of the data explained by surgeon identity).
Algorithm implementation
We obtained initial tests prospectively on 173 consecutive patients for THR and 144 for TKR. Twenty-six patients were excluded after their care was transferred to an independent hospital and six were cancelled by their GP to allow investigation of their anaemia. Four were cancelled for other surgical or medical reasons. We therefore analysed data on 158 patients presenting for THR and 123 for TKR.
Seventy-three patients presented with anaemia. In total, 31 patients were treated with oral iron alone, 13 received parenteral iron (Ferric Carboxymaltose, 'Ferrinject', Vifor Pharma) and 22 received EPO (Recombinant Erythropoietin Alpha, 'Eprex', Janssen-Cilag) and iron. Fourteen nonanaemic women (whose Hb values were 12-13 g dl 21 in
combination with ferritin values suggesting functional iron deficiency and undergoing THR) were given iron in accordance with our agreed pathway. Twenty-one anaemic patients went untreated: 14 of these were for logistical reasons, for example, unavailability of an anaesthetist involved in the project for preoperative consultation; five men had only mild anaemia (Hb.12 g dl 21 ) without evidence of possible iron deficiency and were not offered treatment, in accordance with the algorithm; one patient declined because treatment would interfere with her planned holiday before surgery; and one because of needle phobia (Fig. 5) . Twenty men and 46 women received treatment. Seven operations were re-scheduled for anaemia treatment. Using drug cost figures from our pharmacy, we calculated spendings of £15 070 and £1625 on EPO and parenteral iron, respectively (VAT excluded).
Before-and-after comparisons
Patients and procedures
The post-implementation group was older on average than the baseline group; 74 (66 -80) yr compared with 72 (65 - 
78) yr (P¼0.006).
The two groups were similar in other respects (Table 6 ). Nadir Hb (as determined by our database method) was the last pre-transfusion Hb in all 12 transfused patients in the post-implementation group. Hospital records indicate that intraoperative cell salvage was used for a total of 14 primary arthroplasties from 2008 to 2010; 11 from the baseline period and three while the programme was implemented. There were no major changes in the consultant surgical body during the period in which the algorithm was implemented. All our substantive orthopaedic surgeons had patients in both the before and after groups.
Process measures: preoperative anaemia and perioperative Hb loss
The anaemia prevalence within the post-implementation group decreased from 25.9% (73/281) at listing to 10.3% (29/281) after treatment (P,0.001), on an intention-to-treat basis. There was a significant inverse relationship between the baseline Hb and the Hb response to treatment (P¼0.007; Fig. 6 ). Hb loss after THR decreased from 3.8 (2.9 -4.9) g dl 21 at baseline to 3.1 (2.6 -4.0) g dl 21 after algorithm implementation (P,0.001). For TKR, the Hb loss was 3.1 (1. The LOS for THR and TKR decreased from 6 (5-8) days to 5 (3-7) and 4 (3 -6) days, respectively, after algorithm implementation (P,0.001). The all-cause re-admission rate to hospital within 30 days from discharge fell from 6.8% (49/ 717) to 4.3% (12/281) after algorithm implementation (P¼0.14). The corresponding figures for re-admission within 90 days were 13.5% (97/717) before and 8.2% (23/281) after algorithm implementation (P¼0.02).
Discussion
This quality improvement report describes the design of a patient blood management programme in response to a combination of local data, national guidelines, and international opinion. The resulting systematic approach to optimizing patients' red cell mass and limiting Hb loss perioperatively was associated with lower ABT rates, shorter LOS, and a reduction in re-attendance after elective arthroplasty.
The relationships between anaemia, the factors commonly associated with anaemia (e.g. age, systemic disease), and ABT are complex. Their relative contributions to outcome are thus difficult to specify 8 though preoperative anaemia is common, 7 20 easy to identify, and treatable. There is mounting evidence that preoperative anaemia and ABT are additive risk factors for poor postoperative outcome, including mortality. 1 7 21 The relationship which we found between anaemia, ABT, and poor outcomes is not new, although it has not to our knowledge been previously described in UK practice. Two Scottish groups 22 23 found preoperative Hb levels ,12 gdl 21 and low body weight to predict ABT needs, but considered no other outcomes. Despite this relative paucity of UK outcome data, the Department of Health endorses blood management strategies. Donor blood is a limited resource. 11 The size of the donor pool may also decrease or become precarious because of changes in donor characteristics or infective pandemics. 12 24 Donation is frequently sought on the basis that the gift is used in cases where medical correction of anaemia is impossible. 25 Blood management may thus be said to be worthwhile in itself for the sake of donors and for public health reasons, even if further work on the risk:benefit balance of ABT for recipients in some situations is still needed. 8 9 A key consideration in our programme to implement the national guidance was that it started with an analysis of the possible relationships between anaemia and outcomes in our own hands. Overall, our baseline outcomes for transfusion, 3 16 26 27 LOS, 28 and re-admission 28 29 were comparable with those from elsewhere in England and Europe. The median nadir Hb value associated with transfusion at baseline was also .1 g dl 21 lower than in the OSTHEO study, a large multicentre investigation of transfusion for arthroplasty across Europe. 27 Even though we cannot be sure that the nadir Hb was the value that triggered transfusion, this was always the last pre-transfusion Hb when we had prospective data available. In our view, this indicates that our baseline transfusion practice was not inappropriately liberal. Our uniform overall outcomes masked a significant effect of preoperative anaemia and perioperative ABT. We therefore felt obliged to implement the NHSBT and DOH recommendations on blood management, but could find no published algorithm directly applicable to UK practice. Observational studies 18 19 and one cluster-randomized trial, 17 respectively, from Europe and Canada have shown encouraging results. However, these made a widespread use of autologous predonation which is no longer offered routinely in the UK. 30 We therefore had to design our own algorithm, using our local baseline data to make the case for change and to modify previously published algorithms in a rational fashion. Another consideration was that any programme should be practicable and acceptable to our colleagues. We therefore purposely left much to their discretion, rather than prescribe to them how to manage their own patients. This included decisions on whether to cancel arthroplasty for investigation of any anaemia, aspects of surgical practice (e.g. wound drains), and, for example, the use of cell salvage or intraoperative anti-fibrinolytics. In order to limit the up-front cost of the project (i.e. cash spent on drugs in the hope of clinical improvement and savings further on), we placed emphasis on treating anaemia only where our own baseline data suggested that an outcome improvement was likely. Our criteria for the use of iron were consequently more liberal than those traditionally used for the diagnosis of iron deficiency anaemia per se. The rationale for this is increasing recognition that joint inflammation-related iron sequestration may make serum ferritin values falsely high even in the presence of iron deficiency at the bone marrow level. 7 Iron is also relatively cheap. Most patients had oral iron because we reserved the parenteral formulation for patients intolerant of, nonresponsive to oral iron, or to avoid postponement of surgery. We also reserved the more costly treatment (EPO) for patients with preoperative Hb,12 g dl 21 in whom iron deficiency could be excluded. This approach is relatively conservative compared with previous studies. 18 19 The Network for Advancement of Transfusion Alternatives (NATA) published blood management guidelines for orthopaedic surgery after the start of our programme. 31 The authors cite extensive evidence from mixed surgical populations and recommend a standardized approach to the evaluation and management of elective orthopaedic patients. Our algorithm is different in some respects. NATA recommend that WHO criteria for anaemia diagnosis also be used as treatment thresholds. These thresholds are gender-specific, but transfusion triggers suggested by, for example, the British Committee for Standards in Haematology 32 or used in randomized trials 33 are not. In our series, women and men lost similar amounts of Hb (and hence proportionally similar blood volumes) perioperatively. However, women presented with lower preoperative Hb values and subsequently had higher transfusion rates. Gender-specific treatment thresholds may therefore expose women to disproportionate risk of transfusion and possible consequent morbidity. We rather based our treatment thresholds on the scheduled procedure, since THR was substantially more likely to lead to ABT than TKR in our series. NATA also recommends that the initial Hb level be performed as close as possible to 28 days before surgery and that further investigation proceeds only if the patient is anaemic. We preferred on practical grounds to submit patients to a standard battery of tests including Hb and ferritin as soon as the surgical decision was made to proceed to arthroplasty, in order to fit in with our existing pathways. On this background, our algorithm delivered good results, being associated with .50% improvements in our primary process and outcome measures, without leading to many patients having their surgery postponed (seven in total). Preoperative anaemia prevalence decreased from 26% at first assessment to 10% after treatment, on an intention-to-treat basis. The modest (0.5 -0.7 g dl 21 ) observed decrease in Hb loss would be consistent with an increased use of intraoperative blood conservation measures and/or more careful surgery, but we did not specifically audit individual practice, in accordance with our agreement with colleagues when we started the programme. The combination of less preoperative anaemia and less Hb loss leads to a two-thirds reduction in ABT for THR and effective cessation of ABT for TKR, without a decrease in patients' postoperative Hb levels. In addition to reducing the burden we placed on blood donors, we observed improved measures of patient outcome, namely LOS and re-admission. Since these improved concurrently, it is likely that this was a real outcome change, rather than simply artifact related to the inverse relationship between LOS and re-admissions in the context of elective surgery. 34 The observed improvements occurred, despite the fact that the post-implementation group was significantly older than the baseline group, which in itself would be a risk factor for prolonged LOS and complications. 5 The drug cost of the programme was £16 695 over 8 months. Of this, £12 625 was offset by savings on the purchase of red cells, making the net 'cash cost' of implementing the algorithm £4070 for a cohort of 281 patients. These measures further do not allow for nursing time, consumable equipment (e.g. blood giving sets vs cheaper fluid sets), repeat blood tests, or the treatment of any complications related to transfusion. While these additional activitybased costs of transfusion are difficult to quantify, recent data indicate that they may be as much as four times the product cost. 35 We did not quantify the cost of enteral iron or intraoperative tranexamic acid as both are inexpensive drugs. We also specified the use of relatively expensive formulations of EPO and parenteral iron for reasons of convenience while the pathway was still under evaluation. It is therefore likely that implementing the algorithm was cost-saving once total in-hospital costs are accounted for, and it would be possible for hospitals to design algorithms that are cost-saving even in 'cash terms' by the use of cheaper drug formulations. Although they are surrogate markers of outcome, LOS and readmission rates are also widely used as a discriminator between hospitals, and proposals have been made to penalize hospitals financially for re-admissions, both in the NHS 36 and USA. 37 Our observed LOS and re-admission reductions may therefore represent an additional cost-saving from blood management. This audit has important weaknesses. Our data are observational. The observed improvements may constitute a Hawthorne effect (whereby outcomes are improved by close observation) rather than an effect of the blood management algorithm itself. We also cannot comment on what the relative contributions of iron therapy, EPO, and the intraoperative measures were. We collected no data on medical comorbidities, intraoperative blood loss, patient weight, fluid management, surgical approaches, complications, or the reasons for health-care resource use after discharge, since these are not coded into our hospital databases. Confounding and bias is therefore possible.
However, our audit cycle also has strengths. We collected a substantial baseline data set from records subject to regular external audit, in a way which is more accurate than notes review. 23 Our exclusion criteria ensured high specificity and the resultant series was similar in size and ratio of THR:TKR to that which we reported to a national register, that is, its sensitivity was also good. We could control statistically for potential confounders when we determined the baseline predictors of outcome. We could therefore accurately describe our outcomes and use the baseline group as a control for evaluating the programme's effects. It is possible that our results underestimate the magnitude of change that can be achieved, since (due to having other commitments) we were unable to personally see and start treatment for a substantial number of anaemic patients as our protocol required. We conducted our before-and-after comparisons on the basis of intention to treat. We conclude that preoperative Hb is an easily identifiable predictor of poor outcome after arthroplasty in routine UK practice and that preoperative anaemia treatment is feasible in this setting. The introduction of a patient blood management algorithm was associated with a reduction in the demand we made on blood donors and improvements in patient outcome; LOS and re-admissions both decreased. Randomized trials are necessary to determine whether blood management programmes improve patient outcomes other than ABT rate, and what the optimal algorithm is in terms of cost and patient outcome.
